Home » Stocks » Proteostasis Therapeutics

Proteostasis Therapeutics, Inc. (PTI)

Stock Price: $1.41 USD 0.04 (2.92%)
Updated Aug 10, 2020 4:00 PM EDT - Market closed

Stock Price Chart

Key Info

Market Cap 73.57M
Revenue (ttm) n/a
Net Income (ttm) -43.46M
Shares Out 52.15M
EPS (ttm) -0.85
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Aug 10, 2020
Last Price $1.41
Previous Close $1.37
Change ($) 0.04
Change (%) 2.92%
Day's Open 1.39
Day's Range 1.35 - 1.45
Day's Volume 773,239
52-Week Range 0.61 - 4.72

More Stats

Market Cap 73.57M
Enterprise Value 24.61M
Earnings Date (est) Nov 5, 2020
Ex-Dividend Date n/a
Shares Outstanding 52.15M
Float 44.16M
EPS (basic) -0.84
EPS (diluted) -0.85
FCF / Share -0.84
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 2.68M
Short Ratio 3.15
Short % of Float 4.91%
Beta 1.17
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio n/a
PB Ratio 1.34
Revenue n/a
Operating Income -44.51M
Net Income -43.46M
Free Cash Flow -43.56M
Net Cash 48.96M
Net Cash / Share 0.94
Gross Margin n/a
Operating Margin n/a
Profit Margin n/a
FCF Margin n/a
ROA -32.78%
ROE -68.48%
ROIC -124.00%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (0)

Buy 0
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: n/a

Price Target

(290.07% upside)
Current: $1.41
Target: 5.50
*Average 12-month price target from 4 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Revenue Growth76.06%-46.83%-36.3%94.43%-16.27%351.36%-
Gross Profit5.002.845.348.384.315.151.14
Operating Income-61.15-63.18-59.97-37.46-24.53-15.68-15.58
Net Income-59.13-61.83-59.43-37.23-25.04-15.77-15.72
Shares Outstanding51.1438.5025.4118.760.550.470.42
Earnings Per Share-1.16-1.61-2.34-2.06-42.14-63.74-53.87
Operating Cash Flow-53.22-58.84-52.40-41.93-19.42-8.66-12.91
Capital Expenditures-0.01-0.42-0.12-0.22-0.26-0.17-0.04
Free Cash Flow-53.23-59.26-52.51-42.14-19.68-8.83-12.96
Cash & Equivalents70.3011874.7685.8014.149.092.89
Total Debt-----10.20-
Net Cash / Debt70.3011874.7685.8014.14-1.112.89
Book Value62.3811468.8181.46-108-95.08-73.73
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Proteostasis Therapeutics, Inc.
Country United States
Employees 42
CEO Meenu Chhabra Karson

Stock Information

Ticker Symbol PTI
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: PTI
IPO Date February 11, 2016


Proteostasis Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the discovery and development of novel therapeutics to treat cystic fibrosis. The company's lead product candidates for the treatment of CF include PTI-801, a cystic fibrosis transmembrane conductance regulator (CFTR) corrector agent; PTI-808, a CFTR potentiator; and PTI-428, a CFTR amplifier. It has collaboration agreements with Cystic Fibrosis Foundation, Inc. to research, develop, and commercialize products for the treatment of CF, non-classical CF, and other pulmonary diseases in the United States or the European Union; and Genentech, Inc. for licensing the technology and materials relating to therapeutic small molecule modulators. The company was formerly known as Proteoguard, Inc. and changed its name to Proteostasis Therapeutics, Inc. in September 2007. Proteostasis Therapeutics, Inc. was founded in 2006 and is headquartered in Boston, Massachusetts.